Drug Profile
Noiiglutide - Jiangsu Hansoh Pharmaceutical
Alternative Names: HS 20004; HTI-2088; Noiigliutide-injection; SHR-20004Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Developer Hengrui Therapeutics; Jiangsu Hansoh Pharmaceutical; Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 26 Dec 2023 Jiangsu HengRui Medicine initiates enrolment in a phase I trial in Type 2 diabetes mellitus (In volunteers) in China (SC) (NCT06137469)
- 17 Nov 2023 Jiangsu HengRui Medicine plans a phase I trial for Type 2 diabetes mellitus (In volunteers) in December 2023 (SC, Injection) (NCT06137469)
- 19 Oct 2022 Phase I development is ongoing in China for Type-2-diabetes-mellitus (Jiangsu Hengrui Medicine pipeline, October 2022)